Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

被引：292

作者：

Dimopoulos, M. A. ^{[1
]}

Kastritis, E. ^{[1
]}

Bamia, C. ^{[2
]}

Melakopoulos, I.

Gika, D. ^{[1
]}

Roussou, M. ^{[1
]}

Migkou, M. ^{[1
]}

Eleftherakis-Papaiakovou, E. ^{[1
]}

Christoulas, D. ^{[1
]}

Terpos, E. ^{[3
]}

Bamias, A. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

[2] Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece

[3] 251 Gen Air Force Hosp, Dept Biomed Res, Athens, Greece

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷 / 01期

关键词：

RISK-FACTORS; BISPHOSPHONATES; PAMIDRONATE; NECROSIS; CANCER;

D O I：

10.1093/annonc/mdn554

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Osteonecrosis of the jaw (ONJ) is a well-described complication of bisphosphonates use in patients with multiple myeloma (MM). We investigated whether the occurrence of ONJ decreased after the implementation of preventive measures in 128 patients with MM who received zoledronic acid. Patients and methods: Patients with MM who received zoledronic acid were included in this analysis. Patients with a previous use of other bisphosphonates were excluded; patients were stratified into group A (n = 38) and group B (n = 90) if treatment was started before or after the implementation of preventive measures. Results: One hundred and twenty-eight patients were included in this analysis. Sixteen patients (12.5%) developed ONJ-025EFgroup A: 8 (26.3%), group B: 2 (6.7%) (P = 0.002). The incidence rate (IR) was 0.671/100 person-months for group A and 0.230/100 person-months for group B [IR ratio 2.92, P = 0.029, 95% confidence interval 1.06-8.03]. No patient in group B developed stage III ONJ. Conclusion: In conclusion, the risk of developing ONJ after treatment of zoledronic acid is reduced (but not deleted) by the implementation of preventive measures.

引用

页码：117 / 120

页数：4

共 22 条

[1]

[Anonymous], Prescribing information reslizumab

[2]

[Anonymous], 2006, J AM DENT ASS, V137, P1144

[3] Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].

Badros, A ;

Weikel, D ;

Salama, A ;

Goloubeva, O ;

Schneider, A ;

Rapoport, A ;

Fenton, R ;

Gahres, N ;

Sausville, E ;

Ord, R ;

Meiller, T .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952

[4] Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases [J].

Bagan, JV ;

Murillo, J ;

Jimenez, Y ;

Poveda, R ;

Milian, MA ;

Sanchis, JM ;

Silvestre, FJ ;

Scully, C .

JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2005, 34 (02) :120-123

[5] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

[6] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, MJ ;

Blacklock, HA ;

Bell, R ;

Simeone, J ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493

[7]

CLARKE BKS, BISPHOSPHONATE ASS O

[8] A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma [J].

Corso, A. ;

Varettoni, M. ;

Zappasodi, P. ;

Klersy, C. ;

Mangiacavalli, S. ;

Pica, G. ;

Lazzarino, M. .

LEUKEMIA, 2007, 21 (07) :1545-1548

[9]

Dimopoulos MA, 2006, HAEMATOL-HEMATOL J, V91, P968

[10]

Durie BGM, 2005, NEW ENGL J MED, V353, P99

← 1 2 3 →